FDA Leadership After Marty Makary: What Biotech Needs Next

FDA instability. AI in clinical trials. China overtaking the United States in biotech development.Following news that Marty Makary has stepped down as FDA commissioner, questions around regulatory stability, scientific leadership, and the future of biotech innovation are back in focus.This week on the Making Medicine Podcast, John Stanford examines what the FDA needs most during periods of leadership transition: scientific credibility, regulatory expertise, and a stable, predictable process for developing new medicines.Recorded before the latest leadership announcement, this episode focuses less on personalities and more on the broader institutional questions shaping the future of drug development, clinical trials, AI-enabled regulation, rare disease research, and America’s global competitiveness in biotech.This episode covers:  This episode covers:🔹 What Marty Makary’s departure could mean for the FDA🔹 Why FDA stability matters for biotech investment🔹 The qualities that define effective FDA leadership🔹 AI, clinical trials, and the future of drug development🔹 FDA modernization and new approach methodologies🔹 Rare disease development and regulatory predictability🔹 Why global biotech competition is accelerating🔹 How FDA credibility impacts patients, investors, and innovationAt the center of the conversation is one core issue: confidence. Confidence that the FDA remains a science-driven institution capable of supporting innovation while ensuring drugs are safe and effective for American patients. Because uncertainty at the agency doesn’t just affect markets — it affects clinical timelines, capital allocation, and ultimately whether treatments reach patients.Join the Conversation ⬇️Do you think the FDA is becoming less predictable?Should AI play a larger role in clinical trials?Can America maintain its leadership in biotech innovation?Let us know your thoughts in the comments below 👇If you're new to the Making Medicine Podcast, we're happy you'rehere! Follow us for more:https://x.com/MakingMedPodhttps://www.instagram.com/makingmedicinepod/https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=truehttps://www.tiktok.com/@makingmedicinepodcast?lang=en👍 Like and subscribe for more conversations on FDA policy, biotech investing, healthcare innovation, drug development, gene therapy, AI in medicine, and the future of biotechnology.Timestamps00:00 Intro & Disclaimer00:33 Why FDA Leadership Matters01:00 FDA Leadership Shakeup Explained01:50 Why FDA Stability Impacts Biotech02:14 The Cost Of Regulatory Uncertainty02:59 The Three Qualities Of A Strong FDA Commissioner03:51 Why Regulatory Experience Matters04:40 AI & The Future Of Clinical Trials05:47 America’s Healthcare Data Problem06:17 Why The FDA Must Lead On AI06:41 The Limits Of FDA Authority07:07 Why Investors Need Predictability07:33 FDA Modernization & Innovation07:55 Why This Matters For Patients08:21 Rare Disease Patients & FDA Stability08:41 Passage Bio’s FDA Setback09:27 China Surpasses The U.S. In Drug Trials10:09 What The Industry Wants From The FDA10:32 Why Stable Regulation MattersDISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.#FDA #Biotech #AI #ClinicalTrials #HealthcarePolicy #RareDisease #GeneTherapy #DrugDevelopment #China #MakingMedicine